Copyright Reports & Markets. All rights reserved.

Global Adeno-Associated Virus (AAV) Particles Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Adeno-Associated Virus (AAV) Particles Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Custom-made
    • 1.3.3 Pre-made
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Adeno-Associated Virus (AAV) Particles Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Medical Institutions
    • 1.4.3 Research Institute
  • 1.5 Global Adeno-Associated Virus (AAV) Particles Market Size & Forecast
    • 1.5.1 Global Adeno-Associated Virus (AAV) Particles Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Adeno-Associated Virus (AAV) Particles Sales Quantity (2021-2032)
    • 1.5.3 Global Adeno-Associated Virus (AAV) Particles Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Lonza
    • 2.1.1 Lonza Details
    • 2.1.2 Lonza Major Business
    • 2.1.3 Lonza Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.1.4 Lonza Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Lonza Recent Developments/Updates
  • 2.2 Addgene
    • 2.2.1 Addgene Details
    • 2.2.2 Addgene Major Business
    • 2.2.3 Addgene Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.2.4 Addgene Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Addgene Recent Developments/Updates
  • 2.3 Takara
    • 2.3.1 Takara Details
    • 2.3.2 Takara Major Business
    • 2.3.3 Takara Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.3.4 Takara Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Takara Recent Developments/Updates
  • 2.4 Charles River Laboratories
    • 2.4.1 Charles River Laboratories Details
    • 2.4.2 Charles River Laboratories Major Business
    • 2.4.3 Charles River Laboratories Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.4.4 Charles River Laboratories Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Charles River Laboratories Recent Developments/Updates
  • 2.5 SIRION Biotech
    • 2.5.1 SIRION Biotech Details
    • 2.5.2 SIRION Biotech Major Business
    • 2.5.3 SIRION Biotech Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.5.4 SIRION Biotech Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 SIRION Biotech Recent Developments/Updates
  • 2.6 Thermo Fisher Scientific
    • 2.6.1 Thermo Fisher Scientific Details
    • 2.6.2 Thermo Fisher Scientific Major Business
    • 2.6.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.6.4 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Thermo Fisher Scientific Recent Developments/Updates
  • 2.7 OriGene Technologies
    • 2.7.1 OriGene Technologies Details
    • 2.7.2 OriGene Technologies Major Business
    • 2.7.3 OriGene Technologies Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.7.4 OriGene Technologies Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 OriGene Technologies Recent Developments/Updates
  • 2.8 Cell Biolabs
    • 2.8.1 Cell Biolabs Details
    • 2.8.2 Cell Biolabs Major Business
    • 2.8.3 Cell Biolabs Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.8.4 Cell Biolabs Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Cell Biolabs Recent Developments/Updates
  • 2.9 GenScript
    • 2.9.1 GenScript Details
    • 2.9.2 GenScript Major Business
    • 2.9.3 GenScript Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.9.4 GenScript Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GenScript Recent Developments/Updates
  • 2.10 VectorBuilder
    • 2.10.1 VectorBuilder Details
    • 2.10.2 VectorBuilder Major Business
    • 2.10.3 VectorBuilder Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.10.4 VectorBuilder Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 VectorBuilder Recent Developments/Updates
  • 2.11 GeneCopoeia
    • 2.11.1 GeneCopoeia Details
    • 2.11.2 GeneCopoeia Major Business
    • 2.11.3 GeneCopoeia Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.11.4 GeneCopoeia Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 GeneCopoeia Recent Developments/Updates
  • 2.12 AMSBIO
    • 2.12.1 AMSBIO Details
    • 2.12.2 AMSBIO Major Business
    • 2.12.3 AMSBIO Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.12.4 AMSBIO Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 AMSBIO Recent Developments/Updates
  • 2.13 Creative Biogene
    • 2.13.1 Creative Biogene Details
    • 2.13.2 Creative Biogene Major Business
    • 2.13.3 Creative Biogene Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.13.4 Creative Biogene Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Creative Biogene Recent Developments/Updates
  • 2.14 BPS Bioscience
    • 2.14.1 BPS Bioscience Details
    • 2.14.2 BPS Bioscience Major Business
    • 2.14.3 BPS Bioscience Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.14.4 BPS Bioscience Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 BPS Bioscience Recent Developments/Updates
  • 2.15 Oxford Biomedica
    • 2.15.1 Oxford Biomedica Details
    • 2.15.2 Oxford Biomedica Major Business
    • 2.15.3 Oxford Biomedica Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.15.4 Oxford Biomedica Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Oxford Biomedica Recent Developments/Updates
  • 2.16 FUJIFILM Diosynth Biotechnologies
    • 2.16.1 FUJIFILM Diosynth Biotechnologies Details
    • 2.16.2 FUJIFILM Diosynth Biotechnologies Major Business
    • 2.16.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.16.4 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
  • 2.17 Aldevron
    • 2.17.1 Aldevron Details
    • 2.17.2 Aldevron Major Business
    • 2.17.3 Aldevron Adeno-Associated Virus (AAV) Particles Product and Services
    • 2.17.4 Aldevron Adeno-Associated Virus (AAV) Particles Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Aldevron Recent Developments/Updates

3 Competitive Environment: Adeno-Associated Virus (AAV) Particles by Manufacturer

  • 3.1 Global Adeno-Associated Virus (AAV) Particles Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Manufacturer (2021-2026)
  • 3.3 Global Adeno-Associated Virus (AAV) Particles Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Adeno-Associated Virus (AAV) Particles by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Adeno-Associated Virus (AAV) Particles Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Adeno-Associated Virus (AAV) Particles Manufacturer Market Share in 2025
  • 3.5 Adeno-Associated Virus (AAV) Particles Market: Overall Company Footprint Analysis
    • 3.5.1 Adeno-Associated Virus (AAV) Particles Market: Region Footprint
    • 3.5.2 Adeno-Associated Virus (AAV) Particles Market: Company Product Type Footprint
    • 3.5.3 Adeno-Associated Virus (AAV) Particles Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Adeno-Associated Virus (AAV) Particles Market Size by Region
    • 4.1.1 Global Adeno-Associated Virus (AAV) Particles Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Adeno-Associated Virus (AAV) Particles Consumption Value by Region (2021-2032)
    • 4.1.3 Global Adeno-Associated Virus (AAV) Particles Average Price by Region (2021-2032)
  • 4.2 North America Adeno-Associated Virus (AAV) Particles Consumption Value (2021-2032)
  • 4.3 Europe Adeno-Associated Virus (AAV) Particles Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Adeno-Associated Virus (AAV) Particles Consumption Value (2021-2032)
  • 4.5 South America Adeno-Associated Virus (AAV) Particles Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Adeno-Associated Virus (AAV) Particles Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 5.2 Global Adeno-Associated Virus (AAV) Particles Consumption Value by Type (2021-2032)
  • 5.3 Global Adeno-Associated Virus (AAV) Particles Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 6.2 Global Adeno-Associated Virus (AAV) Particles Consumption Value by Application (2021-2032)
  • 6.3 Global Adeno-Associated Virus (AAV) Particles Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 7.2 North America Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 7.3 North America Adeno-Associated Virus (AAV) Particles Market Size by Country
    • 7.3.1 North America Adeno-Associated Virus (AAV) Particles Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Adeno-Associated Virus (AAV) Particles Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 8.2 Europe Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 8.3 Europe Adeno-Associated Virus (AAV) Particles Market Size by Country
    • 8.3.1 Europe Adeno-Associated Virus (AAV) Particles Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Adeno-Associated Virus (AAV) Particles Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Adeno-Associated Virus (AAV) Particles Market Size by Region
    • 9.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Particles Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Adeno-Associated Virus (AAV) Particles Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 10.2 South America Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 10.3 South America Adeno-Associated Virus (AAV) Particles Market Size by Country
    • 10.3.1 South America Adeno-Associated Virus (AAV) Particles Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Adeno-Associated Virus (AAV) Particles Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Adeno-Associated Virus (AAV) Particles Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Adeno-Associated Virus (AAV) Particles Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Adeno-Associated Virus (AAV) Particles Market Size by Country
    • 11.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Particles Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Adeno-Associated Virus (AAV) Particles Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Adeno-Associated Virus (AAV) Particles Market Drivers
  • 12.2 Adeno-Associated Virus (AAV) Particles Market Restraints
  • 12.3 Adeno-Associated Virus (AAV) Particles Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Adeno-Associated Virus (AAV) Particles and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Adeno-Associated Virus (AAV) Particles
  • 13.3 Adeno-Associated Virus (AAV) Particles Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Adeno-Associated Virus (AAV) Particles Typical Distributors
  • 14.3 Adeno-Associated Virus (AAV) Particles Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Particles market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Adeno-Associated Virus (AAV) particles are small, non-enveloped viruses that belong to the Parvoviridae family. AAV is commonly used in gene therapy and biotechnology as a vector for delivering genetic material into cells. AAV particles are characterized by their ability to infect a broad range of dividing and non-dividing cells, and they are considered relatively safe for therapeutic applications due to their low pathogenicity in humans. In gene therapy, AAV vectors are designed to carry therapeutic genes into target cells, allowing for the correction or replacement of defective genes. AAV particles have shown promise in various medical applications, and ongoing research aims to optimize their efficiency, specificity, and safety for use in treating genetic disorders and other diseases.
    The cell and gene therapy market is experiencing significant growth driven by ongoing advancements in medical research and biotechnology. Key trends include an increasing number of clinical trials and approvals for cell and gene therapies, indicating a growing acceptance of these innovative treatments. There is a notable emphasis on personalized medicine, with therapies tailored to individual patients based on genetic factors. Collaborations and partnerships between pharmaceutical companies and research institutions are on the rise, fostering innovation and the development of novel therapies. Manufacturing scalability and process optimization are focal points to meet the rising demand for these therapies. Additionally, efforts to address regulatory and reimbursement challenges are ongoing, reflecting the dynamic nature of the cell and gene therapy landscape. Overall, the market is evolving rapidly, with a focus on expanding therapeutic applications and improving accessibility for patients globally.
    This report is a detailed and comprehensive analysis for global Adeno-Associated Virus (AAV) Particles market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Adeno-Associated Virus (AAV) Particles market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Adeno-Associated Virus (AAV) Particles market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Adeno-Associated Virus (AAV) Particles market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Adeno-Associated Virus (AAV) Particles market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Adeno-Associated Virus (AAV) Particles
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Adeno-Associated Virus (AAV) Particles market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Addgene, Takara, Charles River Laboratories, SIRION Biotech, Thermo Fisher Scientific, OriGene Technologies, Cell Biolabs, GenScript, VectorBuilder, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Adeno-Associated Virus (AAV) Particles market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Custom-made
    Pre-made
    Market segment by Application
    Medical Institutions
    Research Institute
    Major players covered
    Lonza
    Addgene
    Takara
    Charles River Laboratories
    SIRION Biotech
    Thermo Fisher Scientific
    OriGene Technologies
    Cell Biolabs
    GenScript
    VectorBuilder
    GeneCopoeia
    AMSBIO
    Creative Biogene
    BPS Bioscience
    Oxford Biomedica
    FUJIFILM Diosynth Biotechnologies
    Aldevron
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Adeno-Associated Virus (AAV) Particles product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Adeno-Associated Virus (AAV) Particles, with price, sales quantity, revenue, and global market share of Adeno-Associated Virus (AAV) Particles from 2021 to 2026.
    Chapter 3, the Adeno-Associated Virus (AAV) Particles competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Adeno-Associated Virus (AAV) Particles breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Adeno-Associated Virus (AAV) Particles market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Adeno-Associated Virus (AAV) Particles.
    Chapter 14 and 15, to describe Adeno-Associated Virus (AAV) Particles sales channel, distributors, customers, research findings and conclusion.

    Buy now